104 related articles for article (PubMed ID: 38962968)
1. Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice.
Wirrell EC; Lagae L; Scheffer IE; Cross JH; Specchio N; Strzelczyk A
Epilepsia Open; 2024 Jul; ():. PubMed ID: 38962968
[TBL] [Abstract][Full Text] [Related]
2. Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.
Frampton JE
Drugs; 2023 Jul; 83(10):923-934. PubMed ID: 37316680
[TBL] [Abstract][Full Text] [Related]
3. What have we learned from the real-world efficacy of FFA in DS and LGS? A post-marketing study in clinical practice.
Valls Carbó A; Beltrán Á; Sánchez-Miranda Román I; Cabal B; Gómez-Porro P; Aledo-Serrano Á; López Sobrino G; Ayuga F; Gómez Eguilaz M; Gil-Nagel A
Epilepsy Behav; 2024 Feb; 151():109620. PubMed ID: 38194770
[TBL] [Abstract][Full Text] [Related]
4. Fenfluramine for the treatment of status epilepticus: use in an adult with Lennox-Gastaut syndrome and literature review.
Strzelczyk A; Becker H; Tako L; Hock S; Hattingen E; Rosenow F; Mann C
Neurol Res Pract; 2024 Feb; 6(1):10. PubMed ID: 38383582
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies.
Sills GJ
Ther Adv Neurol Disord; 2023; 16():17562864231191000. PubMed ID: 37655228
[TBL] [Abstract][Full Text] [Related]
6. Patient and Caregiver Health State Utilities in Lennox-Gastaut Syndrome and Dravet Syndrome.
Lo SH; Lloyd A; Marshall J; Vyas K
Clin Ther; 2021 Nov; 43(11):1861-1876.e16. PubMed ID: 34774333
[TBL] [Abstract][Full Text] [Related]
7. Evaluating fenfluramine hydrochloride as an oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome.
Besag FMC; Vasey MJ; Chin RFM
Expert Rev Neurother; 2024 Mar; 24(3):235-249. PubMed ID: 38315124
[TBL] [Abstract][Full Text] [Related]
8. Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey.
Berg AT; Dixon-Salazar T; Meskis MA; Danese SR; Le NMD; Perry MS
Epilepsy Res; 2024 Feb; 200():107280. PubMed ID: 38183688
[TBL] [Abstract][Full Text] [Related]
9. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA).
Hahn CD; Jiang Y; Villanueva V; Zolnowska M; Arkilo D; Hsiao S; Asgharnejad M; Dlugos D
Epilepsia; 2022 Oct; 63(10):2671-2683. PubMed ID: 35841234
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
[TBL] [Abstract][Full Text] [Related]
11. Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome.
Lattanzi S; Zaccara G; Russo E; La Neve A; Lodi MAM; Striano P
Expert Rev Neurother; 2021 Jan; 21(1):99-110. PubMed ID: 33026899
[TBL] [Abstract][Full Text] [Related]
12. Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome.
Nabbout R; Arzimanoglou A; Auvin S; Berquin P; Desurkar A; Fuller D; Nortvedt C; Pulitano P; Rosati A; Soto V; Villanueva V; Cross JH
Seizure; 2023 Aug; 110():78-85. PubMed ID: 37331197
[TBL] [Abstract][Full Text] [Related]
13. Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.
Knupp KG; Scheffer IE; Ceulemans B; Sullivan J; Nickels KC; Lagae L; Guerrini R; Zuberi SM; Nabbout R; Riney K; Agarwal A; Lock M; Dai D; Farfel GM; Galer BS; Gammaitoni AR; Polega S; Davis R; Gil-Nagel A
Epilepsia; 2023 Jan; 64(1):139-151. PubMed ID: 36196777
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
Chen JW; Borgelt LM; Blackmer AB
Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Fenfluramine in Epilepsy: A Systematic Review and Meta-analysis.
Tabaee Damavandi P; Fabin N; Giossi R; Matricardi S; Del Giovane C; Striano P; Meletti S; Brigo F; Trinka E; Lattanzi S
Neurol Ther; 2023 Apr; 12(2):669-686. PubMed ID: 36853503
[TBL] [Abstract][Full Text] [Related]
16. A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication.
Strzelczyk A; Schubert-Bast S
CNS Drugs; 2022 Mar; 36(3):217-237. PubMed ID: 35156171
[TBL] [Abstract][Full Text] [Related]
17. The impact of seizure frequency on quality of life in patients with Lennox-Gastaut syndrome or Dravet syndrome.
Auvin S; Damera V; Martin M; Holland R; Simontacchi K; Saich A
Epilepsy Behav; 2021 Oct; 123():108239. PubMed ID: 34375802
[TBL] [Abstract][Full Text] [Related]
18. Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain.
García-Peñas JJ; Gil Nagel-Rein A; Sánchez-Carpintero R; Villanueva-Haba V
Rev Neurol; 2021 Sep; 73(S01):S1-S8. PubMed ID: 34486101
[TBL] [Abstract][Full Text] [Related]
19. Treatment Guidelines for Rare, Early-Onset, Treatment-Resistant Epileptic Conditions: A Literature Review on Dravet Syndrome, Lennox-Gastaut Syndrome and CDKL5 Deficiency Disorder.
Chin RF; Mingorance A; Ruban-Fell B; Newell I; Evans J; Vyas K; Nortvedt C; Amin S
Front Neurol; 2021; 12():734612. PubMed ID: 34759881
[No Abstract] [Full Text] [Related]
20. A systematic literature review on the global epidemiology of Dravet syndrome and Lennox-Gastaut syndrome: Prevalence, incidence, diagnosis, and mortality.
Sullivan J; Benítez A; Roth J; Andrews JS; Shah D; Butcher E; Jones A; Cross JH
Epilepsia; 2024 May; 65(5):1240-1263. PubMed ID: 38252068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
